Condition
Recurrent Malignant Mesothelioma|Stage IA Malignant Mesothelioma|Stage IB Malignant Mesothelioma|Stage II Malignant Mesothelioma|Stage III Malignant Mesothelioma|Stage IV Malignant Mesothelioma
Estimated Enrollment: 36
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: MC1023|NCI-2011-03574
Study First Received: December 16, 2011
Last Updated: August 25, 2016
Estimated Primary Completion Date: January 2019
Primary Outcome Measures:
Adverse event (AE) profile|Describe the safety of the intrapleural administration of MV-NIS in patients with malignant pleural mesothelioma for all cycles out to 90 days.
Sponsors and Collaborators:
Mayo Clinic|National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT01503177
